Gene:
CCL4
chemokine (C-C motif) ligand 4

PharmGKB contains no prescribing info for this . Contact us to report known genotype-based dosing guidelines, or if you are interested in developing guidelines.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

Overview

Alternate Names:  LAG1; SCYA4
Alternate Symbols:  AT744.1; Act-2; MIP-1-beta
PharmGKB Accession Id: PA35562

Details

Cytogenetic Location: chr17 : q12 - q12
GP mRNA Boundary: chr17 : 34431220 - 34433014
GP Gene Boundary: chr17 : 34421220 - 34436014
Strand: plus

Visualization

UCSC has a Genome Browser that you can use to view PharmGKB annotations for this gene in context with many other sources of information.

View on UCSC Browser
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.
No related genes are available

Curated Information ?

Evidence Drug
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ibrutinib

Curated Information ?

Publications related to CCL4: 2

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach. British journal of haematology. 2014. Sivina Mariela, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genome-wide expression studies of atherosclerosis: critical issues in methodology, analysis, interpretation of transcriptomics data. Arteriosclerosis, thrombosis, and vascular biology. 2006. Bijnens A P J J, et al. PubMed

LinkOuts

NCBI Gene:
6351
OMIM:
182284
UCSC Genome Browser:
NM_002984
RefSeq RNA:
NM_002984
RefSeq Protein:
NP_002975
RefSeq DNA:
NT_010799
Ensembl:
ENSG00000129277
GenAtlas:
CCL4
GeneCard:
CCL4
MutDB:
CCL4
ALFRED:
LO031212J
HuGE:
CCL4
Comparative Toxicogenomics Database:
6351
ModBase:
P13236
HumanCyc Gene:
HS05265
HGNC:
10630

Common Searches